Novel endotypes of antisynthetase syndrome identified independent of anti-aminoacyl transfer RNA synthetase antibody specificity that improve prognostic stratification
Authors' conclusion
Anti-ARS antibodies were not significant in stratifying ASS patients into subgroups with greater homogeneity in RP-ILD and prognoses. Novel ASS endotypes were identified independent of anti-ARS specificity and differed in clinical outcomes and transcriptional signatures
Study context
- Population
- Patients with antisynthetase syndrome (ASS), retrospectively enrolled; healthy controls for transcriptome sequencing
- Participants
- 701 patients
- Exposure
- Anti-ARS antibody subtypes (anti-Jo1, anti-PL7, anti-PL12, anti-EJ); clustering into endotypes independent of anti-ARS specificity
- Outcome
- Endotypes identified by unsupervised machine learning
Methodological detailsunsupervised machine learning clustering, transcriptome sequencing
- Unsupervised machine learning clustering
- Transcriptome sequencing
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Rapidly progressive interstitial lung disease (RP-ILD) incidence and prognosis by anti-ARS antibody subtype
- No significant differences in incidence of RP-ILD or prognoses among the four anti-ARS antibody subtypes
Original publication
Novel endotypes of antisynthetase syndrome identified independent of anti-aminoacyl transfer RNA synthetase antibody specificity that improve prognostic stratification. Ann Rheum Dis. Published 15 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →